Atrial electro-functional predictors of incident atrial fibrillation in cardiac amyloidosis.

Atrial Fibrillation Cardiac Magnetic Resonance Cardiac amyloidosis Electrocardiogram Interatrial Block

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
01 Feb 2024
Historique:
received: 07 11 2023
revised: 12 01 2024
accepted: 29 01 2024
medline: 4 2 2024
pubmed: 4 2 2024
entrez: 3 2 2024
Statut: aheadofprint

Résumé

Atrial fibrillation (AF) is common in patients with cardiac amyloidosis (CA) and is a significant risk factor for heart failure hospitalization and thromboembolic events. to investigate the atrial electro-functional predictors of incident AF in CA. A multicenter, observational study performed in 4 CA referral centers including sinus rhythm patients with light-chain (AL) and transthyretin (ATTR) CA undergoing electrocardiogram (ECG) and cardiac magnetic resonance (CMR). The primary endpoint was new-onset AF occurrence. Overall, 96 patients (AL-CA: n=40; ATTR-CA n=56) were enrolled. During an 18-month median follow-up (Q1-Q3:7-29), 30 patients (29%) had incident AF. Compared with those without, patients with AF were older (79 vs 73 years, p=0.001) and more frequently with ATTR (73% vs 27%, p<0.001), ECG inter-atrial block (IAB), either partial (47% vs 21%, p=0.011) or advanced (17% vs 3%,p=0.017), and lower left atrium ejection fraction (LAEF) (29% vs 41%, p=0.004). Age (HR=1.059; 95%CI 1.002-1.118,p=0.042), any type of IAB (HR=2.211; 95%CI 1.03-4.75, p=0.041) and LAEF (HR=0.967; 95%CI 0.936-0.998, p=0.044) emerged as independent predictors of incident AF. Patients exhibiting any type of IAB, LAEF<40%, and aged>78 years showed a cumulative incidence for AF of 40% at 12 months. This risk was significantly higher than that carried by one (8.5%) or none (7.6%) of these three risk factors. In patients with CA, older age, IAB on 12-lead ECG and reduced LAEF on CMR are significant and independent predictors of incident AF. A closer screening for AF is advisable in CA patients carrying these features.

Sections du résumé

BACKGROUND BACKGROUND
Atrial fibrillation (AF) is common in patients with cardiac amyloidosis (CA) and is a significant risk factor for heart failure hospitalization and thromboembolic events.
OBJECTIVE OBJECTIVE
to investigate the atrial electro-functional predictors of incident AF in CA.
METHODS METHODS
A multicenter, observational study performed in 4 CA referral centers including sinus rhythm patients with light-chain (AL) and transthyretin (ATTR) CA undergoing electrocardiogram (ECG) and cardiac magnetic resonance (CMR). The primary endpoint was new-onset AF occurrence.
RESULTS RESULTS
Overall, 96 patients (AL-CA: n=40; ATTR-CA n=56) were enrolled. During an 18-month median follow-up (Q1-Q3:7-29), 30 patients (29%) had incident AF. Compared with those without, patients with AF were older (79 vs 73 years, p=0.001) and more frequently with ATTR (73% vs 27%, p<0.001), ECG inter-atrial block (IAB), either partial (47% vs 21%, p=0.011) or advanced (17% vs 3%,p=0.017), and lower left atrium ejection fraction (LAEF) (29% vs 41%, p=0.004). Age (HR=1.059; 95%CI 1.002-1.118,p=0.042), any type of IAB (HR=2.211; 95%CI 1.03-4.75, p=0.041) and LAEF (HR=0.967; 95%CI 0.936-0.998, p=0.044) emerged as independent predictors of incident AF. Patients exhibiting any type of IAB, LAEF<40%, and aged>78 years showed a cumulative incidence for AF of 40% at 12 months. This risk was significantly higher than that carried by one (8.5%) or none (7.6%) of these three risk factors.
CONCLUSIONS CONCLUSIONS
In patients with CA, older age, IAB on 12-lead ECG and reduced LAEF on CMR are significant and independent predictors of incident AF. A closer screening for AF is advisable in CA patients carrying these features.

Identifiants

pubmed: 38309449
pii: S1547-5271(24)00110-3
doi: 10.1016/j.hrthm.2024.01.056
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Giulio Sinigiani (G)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Laura De Michieli (L)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Aldostefano Porcari (A)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.

Chiara Zocchi (C)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Anna Sorella (A)

Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.

Carlotta Mazzoni (C)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Giandomenico Bisaccia (G)

Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.

Antonio De Luca (A)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.

Gianluca Di Bella (G)

Rare Cardiac Disease Center, Cardiology Unit, University of Messina, Messina, Italy.

Dario Gregori (D)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Federico Perfetto (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Marco Merlo (M)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.

Gianfranco Sinagra (G)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.

Sabino Iliceto (S)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Martina Perazzolo Marra (M)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Domenico Corrado (D)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Fabrizio Ricci (F)

Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.

Francesco Cappelli (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Alberto Cipriani (A)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy. Electronic address: alberto.cipriani@unipd.it.

Classifications MeSH